Cannabis in menopause

In a US survey (Bryant 2022) 27 % of women with menopausal symptoms used cannabis — mostly for sleep issues, hot flashes and anxiety. Clinical evidence is thin; low-dose CBD or balanced evening preparations are most commonly reported. Caution with osteoporosis risk and blood pressure. In Switzerland only under medical supervision.

TL;DR

Menopause study (Bryant 2022): 27 % of women 45–64 use cannabis for symptoms.
Common uses: sleep issues (~70 %), anxiety (~50 %), hot flashes (~30 %).
CBD-dominant oils (25–50 mg at night) often more effective than THC.
Alternative to hormone replacement therapy — not replacement.

Menopause protocols

Sleep: 25 mg CBD + 2.5 mg THC (full-spectrum) 30–60 min before bed.
Hot flashes: 10–20 mg CBD 2× daily as base.
Mood/anxiety: CBG-CBD combo 1:1, 15–20 mg in the morning.
Before starting: discuss with gynecologist (HRT interaction possible).

Endocrinological relationships and the endocannabinoid system

Menopause is characterised by a profound drop in oestrogen levels, which has far-reaching effects on well-being. Scientific evidence indicates that the endocannabinoid system interacts closely with the female hormonal balance. Oestrogen regulates, among other things, the enzyme fatty acid amide hydrolase, which is responsible for breaking down the body's own cannabinoid anandamide. If oestrogen levels drop, this can lead to dysregulation of the endocannabinoid system. This in turn affects thermoregulation, mood, and pain perception, as cannabinoid receptors are abundant in brain areas such as the hypothalamus.

The targeted administration of plant-derived cannabinoids such as cannabidiol (CBD) or small amounts of tetrahydrocannabinol (THC) targets these receptors. While CBD primarily has a modulating effect and can inhibit the breakdown of the body's own cannabinoids, THC mimics the effect of anandamide at the CB1 receptors. This interaction provides a pharmacological explanation for why some individuals experience a stabilisation of their symptoms. Nevertheless, the clinical data on the direct influence of phytocannabinoids on the hormonal regulatory circuit remains limited and requires careful therapeutic consideration on an individual basis.

Interaction between oestrogen levels and the activity of the endocannabinoid system.
Density of cannabinoid receptors in the hypothalamus influences the body's own temperature regulation.
Modulation of anandamide degradation by cannabidiol as a potential approach.
Need for further clinical research to confirm hormonal interactions.

Swiss legal framework and medical practice for menopausal symptoms

In Switzerland, the legal framework for the medical use of cannabis changed fundamentally in August 2022. Since then, the prescription of medical cannabis by doctors has been possible without an exceptional permit from the Federal Office of Public Health (BAG). Menopausal patients suffering from severe symptoms such as therapy-resistant sleep disorders or chronic pain can obtain corresponding preparations directly through specialised gynaecologists or general practitioners. This development significantly facilitates access to quality-controlled, standardised formulations from Swiss pharmacies.

When using these products, however, the strict Swiss road traffic legislation must be observed. A zero-tolerance policy applies, with a statutory THC limit of 1.5 micrograms per litre of blood, which leads to unfitness to drive even with low consumption of THC-containing products. Anyone using CBD preparations must ensure that the total THC content is below one percent so that the product does not fall under the Narcotics Act (BetmG). Close medical supervision is advisable to rule out interactions with other medications, particularly hormone replacement therapy.

Facilitated access to medical cannabis since August 2022 without an FOPH exceptional permit.
A strict THC limit of 1.5 micrograms per litre of blood restricts participation in road traffic.
Over-the-counter CBD products in Switzerland must have a total THC content of less than one percent.
Medical supervision is urgently recommended to avoid interactions with conventional therapeutics.

Differentiated application and risk assessment in the aging process

The menopause phase is frequently accompanied by an increased risk of cardiovascular diseases and a decrease in bone density. When therapeutically considering cannabis preparations, these physiological changes must be taken into account. While some cannabinoids possess vasodilatory properties that can affect blood pressure in the short term, the data regarding their influence on bone metabolism is inconsistent. Animal studies suggest that the endocannabinoid system plays a role in bone formation and resorption, but reliable long-term clinical studies in humans are lacking.

In addition, the route of administration should be carefully selected. Smoking cannabis flowers is strongly discouraged due to toxic combustion products that place an additional burden on the cardiovascular system. Oral applications such as standardized oils, capsules, or tinctures offer more precise dosing and a more consistent release of active ingredients. Since cannabinoids are metabolized in the liver and can inhibit key enzymes there, extreme caution is advised when co-administering antihypertensives, antidepressants, or hormone preparations to avoid the unwanted accumulation of active substances.

The influence of cannabinoids on the cardiovascular system requires close monitoring of blood pressure.
Unclear evidence regarding the effects on bone density in cases of osteoporosis risk.
Preference for smoke-free administration forms such as oils to protect the respiratory tract and blood vessels.
Potential interactions due to the inhibition of liver enzymes in polypharmacy.

FAQ

Cannabis instead of HRT?

Cannabis can ease symptoms but does not replace estrogen's bone-protective effect. Combination is more realistic.

Can cannabis completely replace conventional hormone replacement therapy (HRT)?

No, according to the current state of scientific knowledge, cannabis cannot serve as an equivalent replacement for hormone replacement therapy. While cannabinoids such as CBD or THC can provide symptomatic relief for sleep disorders, inner restlessness, or pain, they do not possess the specific organ- and bone-protecting properties of estrogens. Hormone replacement therapy aims to directly compensate for the hormonal deficiency in order to prevent long-term risks such as osteoporosis. Cannabis should therefore, at most, be considered a complementary option for symptom relief under medical supervision.

What legal regulations apply in Switzerland to the purchase of CBD oil for menopausal symptoms?

In Switzerland, CBD products such as oils are legally available, provided their total THC content is below one percent. These products do not fall under the Narcotics Act and can be purchased as dietary supplements or cosmetics. In contrast, a medical prescription is required for preparations with a higher THC content. Since the amendment of the law in August 2022, Swiss doctors can prescribe such medical cannabis preparations directly, without the need to obtain an exceptional permit from the Federal Office of Public Health (FOPH).

What side effects and drug interactions must menopausal women be aware of?

Common side effects of cannabinoids include dry mouth, fatigue, dizziness, and temporary fluctuations in blood pressure. However, interactions in the liver are particularly relevant for menopausal women. Cannabinoids block certain enzymes of the cytochrome P450 system. If medications such as antihypertensives, thyroid hormones, or psychotropic drugs are taken at the same time, their breakdown can be delayed. In the worst-case scenario, this can lead to a dangerous overdose of the regular medication. Consultation with the treating physician is therefore essential.